


## Pyrazoloacridine

<b>Cat. No.:</b>	HY-108969		
<b>CAS No.:</b>	99009-20-8		
<b>Molecular Formula:</b>	C <sub>19</sub> H <sub>21</sub> N <sub>5</sub> O <sub>3</sub>		
<b>Molecular Weight:</b>	367.4		
<b>Target:</b>	Topoisomerase; Apoptosis		
<b>Pathway:</b>	Cell Cycle/DNA Damage; Apoptosis		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : < 1 mg/mL (ultrasonic) (insoluble or slightly soluble)
-----------------	---

### BIOLOGICAL ACTIVITY

**Description** Pyrazoloacridine (NSC 366140), an intercalating agent with anti-cancer activity, inhibits the activity of topoisomerases 1 and 2. Pyrazoloacridine (NSC 366140) exhibits an IC<sub>50</sub> of 1.25 μM in K562 myeloid leukemia cells for 24 h treatment<sup>[1][2]</sup>.

**In Vitro** Pyrazoloacridine (NSC 366140, PD 115934) exhibits IC<sub>50</sub> values of 10.7 μM and 4.5 μM for oxic and hypoxic HCT-8 cells<sup>[1]</sup>. Pyrazoloacridine (NSC 366140, 2-4 μM) abolishes the catalytic activity of both topo I and topo II in vitro<sup>[2]</sup>. Pyrazoloacridine (NSC 366140) displays activity against cisplatin- and paclitaxel-resistant ovarian cancer<sup>[2]</sup>. Pyrazoloacridine (NSC 366140) has been shown to cause delayed DNA fragmentation in MCF-7 breast cancer cells<sup>[2]</sup>. Pyrazoloacridine (NSC 366140) induces apoptosis in P53-deficient Hep 3B human hepatoma cells<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay<sup>[2]</sup>

Cell Line:	K562 Myeloid Leukemia Cells.
Concentration:	0-500 μM.
Incubation Time:	1 h or 24 h.
Result:	When K562 cells were incubated with PA for 1 h and then plated in soft agar, an IC <sub>50</sub> of ~50 μM was observed. In contrast, when cells were incubated for 24 h with PA, the IC <sub>50</sub> was 1.25 μM.

### REFERENCES

[1]. J S Sebolt, et al. Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro. *Cancer Res.* 1987 Aug 15;47(16):4299-304.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA